Company: ARAI
Filing Date: 2025-03-21
Form Type: CORRESP
Source: 0001641172-25-000180
Chunk: 0

Company: Arrive AI Inc.
Filing Date: 2025-03-21
Form: CORRESP
Chunk 0
---
<div align='center'>Arrive AI Inc.

12175 Visionary Way

Fishers, Indiana 46038</div>

March 21, 2025

Cara Wirth

U.S. Securities & Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

| Re: | Arrive AI Inc.                  
 Amendment No. 1 to Registration 
 Statement on Form S-1           
 Submitted January 27,           
 2025                            |
|:----|:--------------------------------|
|     | File                            
 No. 333-284042                  
 CIK                             
 No. 001818274                   |

Dear Ms. Wirth:

By letter dated February 20, 2025, the staff (the “ Staff,” “ you” or “ your”) of the U.S. Securities & Exchange Commission (the “ Commission”) provided Arrive AI Inc. (the “ Company,” “ we,” “ us”or “ our”) with its comments to the Company’s Form S-1 filed on January 27, 2025. We are in receipt of your letter and set forth below are the Company’s responses to the Staff’s comments. For your convenience, the comments are listed below, followed by the Company’s responses in bold.

Amendment No. 1 to Registration Statement on Form S-1 Filed January 27, 2025

Risk Factors

If we materially breach the Exclusive Patent License Agreement..., page 13

| 1. | We                                                                                                                               
 note that you added this risk factor in response to prior comment 7. Please revise to remove the mitigating language “[a]lthough 
 unlikely to happen” as it mitigates the risk presented here. Additionally, please appropriately state the risk to investors      
 if Mr. O’Toole terminates the Exclusive Patent License Agreement.                                                                |

| RESPONSE: The Company                                                                                                            
 has revised its disclosure by removing all mitigating language in the risk factor section and expanded the explanation regarding 
 the risk to investors if Mr. O’Toole terminates the Exclusive Patent License Agreement.                                          |

Business, page 31

| 2. | We                                                                                                                                  
 note your amended disclosure in response to prior comment 3 and we reissue in part. With respect to your customer agreements/SOWs   
 and your agreements for installing AP3 units that you plan to provide to MaaS in 2025, please revise to disclose the material terms 
 of such agreements. To the extent that you believe certain portions of the agreements are confidential,